Monitor the next quarterly earnings call for commentary on Endocrinology division performance under new leadership and any strategic shifts in the commercial approach to Cushing's syndrome.
Price Chart
Executive Summary
Corcept announced the retirement of Sean Maduck, President of Endocrinology, effective October 1, 2026, with Justin Gunn succeeding him. Maduck will remain as a senior commercial advisor under a consulting agreement paying $57,000/month through September 2027, with stock options continuing to vest. This is a routine leadership transition with no disagreement cited and a successor already in place.
Key Facts
- Sean Maduck, President of Corcept Endocrinology, resigned effective October 1, 2026, and will retire.
- Justin Gunn appointed President, Endocrinology, effective October 1, 2026; he joined Corcept in July 2024 as VP of Sales for Oncology.
- Maduck entered a Consulting Services Agreement with $57,000/month cash fee through September 30, 2027, with stock options continuing to vest.
- Maduck did not resign due to any disagreement with the company regarding operations, financial statements, policies, or practices.
- Gunn previously led the commercial launch of Lifyorli for platinum-resistant ovarian cancer and spent 18 years at Gilead Sciences.
Financial Impact
Consulting fee of $57,000 per month for up to 12 months (~$684,000 total) plus continued option vesting; immaterial relative to Corcept's scale.
Risk Factors
- Transition risk if Gunn's oncology background does not fully translate to endocrinology commercial strategy.
- Potential distraction during the transition period, though mitigated by Maduck's advisory role.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-398561 |
| Document: d148256dex991.htm | 0001193125-26-398561 |
| Document: 0001193125-26-398561-index-headers.html | 0001193125-26-398561 |
| Document: 0001193125-26-398561-index.html | 0001193125-26-398561 |
| Document: 0001193125-26-398561.txt | 0001193125-26-398561 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 5, 2026 21d ago | Insider Cluster | $119.57 | awaiting T+20 | — | $87.13 (−27.13%) |
Sep 23, 2026 4w ago | 8-K | $112.94 $116.28 | ▲ +2.96% | ▲ +2.27% | $87.13 (−22.85%) |
Sep 16, 2026 5w ago | Insider Cluster | $114.86 $113.37 | ▲ +1.30% | ▲ +2.50% | $87.13 (+24.14%) |
Sep 16, 2026 5w ago | Insider Cluster | $114.86 $113.37 | ▲ +1.30% | ▲ +2.75% | $87.13 (+24.14%) |
Aug 28, 2026 8w ago | Insider Cluster | $113.35 $114.74 | ▲ +1.23% | ▲ +1.60% | $87.13 (−23.13%) |
Aug 28, 2026 8w ago | Insider Cluster | $113.35 $114.74 | ▲ +1.23% | ▲ +1.60% | $87.13 (−23.13%) |
Aug 27, 2026 8w ago | Insider Cluster | $113.88 $115.63 | ▲ +1.54% | ▲ +2.02% | $87.13 (−23.49%) |
Aug 20, 2026 9w ago | Insider Cluster | $122.25 $113.76 | ▼ −6.94% | ▼ −7.96% | $87.13 (−28.73%) |
Aug 18, 2026 9w ago | Insider Cluster | $119.02 $114.86 | ▲ +3.50% | ▲ +2.66% | $87.13 (+26.79%) |
Aug 12, 2026 10w ago | Insider Cluster | $110.51 $112.79 | ▲ +2.06% | ▲ +3.81% | $87.13 (−21.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers